Design of geriatric drug potentially increasing adiponectin expression

Authors

  • Діана Іванівна Данилко Kyiv National University of Technology and Design Nemirovich-Danchenko str., 2, Kyiv, Ukraine, 01011, Ukraine https://orcid.org/0000-0003-2684-5389
  • Володимир Іванович Бессарабов Kyiv National University of Technology and Design Nemyrovych-Danchenko st., 2, Kiev, Ukraine, 01011, Ukraine https://orcid.org/0000-0003-0637-1729
  • Тетяна Андріївна Пальчевська Kyiv National University of Technology and Design Nemirovich-Danchenko str., 2, Kyiv, Ukraine, 01011, Ukraine https://orcid.org/0000-0001-9532-7812

DOI:

https://doi.org/10.15587/2519-4852.2016.81471

Keywords:

adiponectin, metabolic syndrome, insulin resistance, endotoxicity, exotoxicity, in silico, virtual screening

Abstract

Aim. The aim is to create in silico composition of the complex geriatric drug that is able to increase adiponectin expression in patients with symptoms of the metabolic syndrome.

Methods. The study was carried out by using in silico virtual screening with Prediction of Activity Spectra for Substances (PASS).

Results. The first phase of the study included 65 substances that were analyzed for the probability of ADIPOQ gene activation separately according to the protein and mRNA. The research allowed selecting the perspective APIs that are probable to increase expression of adiponectin with a maximum activity (Ra), namely active components of Valeriana officinalis L. extract – isovaleric acid, valeric acid, and γ-aminobutyric acid. Endo- and exotoxicity assessment revealed that the designed drug API have low toxicity.

Conclusion. Proposed composition of the geriatric drug increasing the expression of adiponectin (based on ADIPOQ gene activation), is perspective for further pharmacological, biopharmaceutical properties research and development of dosage forms

Author Biographies

Діана Іванівна Данилко, Kyiv National University of Technology and Design Nemirovich-Danchenko str., 2, Kyiv, Ukraine, 01011

Department of Industrial Pharmacy

Володимир Іванович Бессарабов, Kyiv National University of Technology and Design Nemyrovych-Danchenko st., 2, Kiev, Ukraine, 01011

PhD, associate professor

Department of Industrial Pharmacy

Тетяна Андріївна Пальчевська, Kyiv National University of Technology and Design Nemirovich-Danchenko str., 2, Kyiv, Ukraine, 01011

PhD, associate professor

Department of Industrial Pharmacy

References

  1. Kosygina, A. V., Vasjukova, O. V. (2009). New in the pathogenesis ozhyreniya: adiponectin – a hormone of adipose tissue. Probl. Endokrinnoіpatologіі, 1, 44–50.
  2. Schwartz, B. (2009). Adipose tissue as an immune system organ. Cytokines and Inflammation, 4, 25–31.
  3. Roitberg, G. E. (Ed.) (2007). Metabolic Syndrome. Moscow: Medpress-inform, 224.
  4. Butrova, S. A. (2001). Metabolic syndrome: pathogenesis, clinical features, diagnosis, treatment approaches. Breast cancer, 2, 56–60.
  5. Arita, Y., Kihara, S., Ouchi, N., Takahashi, M., Maeda, K., Miyagawa, J. et. al. (1999). Paradoxical Decrease of an Adipose-Specific Protein, Adiponectin, in Obesity. Biochemical and Biophysical Research Communications, 257 (1), 79–83. doi: 10.1006/bbrc.1999.0255
  6. Pastors, J. G., Franz, M. J., Alexandria, V. A.; Franz, M. J., Evert, A. B. (Eds.) (2012). Effectiveness of medical nutrition therapy in diabetes. American Diabetes Association guide to nutrition therapy for diabetes. American Diabetes Association, 1–18.
  7. Hotta, K., Funahashi, T., Arita, Y., Takahashi, M., Matsuda, M., Okamoto, Y. et. al. (2000). Plasma Concentrations of a Novel, Adipose-Specific Protein, Adiponectin, in Type 2 Diabetic Patients. Arteriosclerosis, Thrombosis, and Vascular Biology, 20 (6), 1595–1599. doi: 10.1161/01.atv.20.6.1595
  8. Nishizawa, H., Shimomura, I., Kishida, K., Maeda, N., Kuriyama, H., Nagaretani, H. et. al. (2002). Androgens Decrease Plasma Adiponectin, an Insulin-Sensitizing Adipocyte-Derived Protein. Diabetes, 51 (9), 2734–2741. doi: 10.2337/diabetes.51.9.2734
  9. Weyer, C., Funahashi, T., Tanaka, S., Hotta, K., Matsuzawa, Y., Pratley, R. E., Tataranni, P. A. (2001). Hypoadiponectinemia in Obesity and Type 2 Diabetes: Close Association with Insulin Resistance and Hyperinsulinemia. The Journal of Clinical Endocrinology & Metabolism, 86 (5), 1930–1935. doi: 10.1210/jcem.86.5.7463
  10. Tanjanskij, D. A., Firova, Je. M., Shatilina, L. V., Denisenko, A. D. (2008). Adiponektin: snizhenie soderzhanija pri metabolicheskom sindrome i nezavisimaja svjaz' s gipertrigliceridemiej. Kardiologija, 12, 20–25.
  11. PubChem. Available at: http://pubchem.ncbi.nlm.nih.gov/
  12. Harris, R. (2003). Screening Adults for Type 2 Diabetes: A Review of the Evidence for the U.S. Preventive Services Task Force. Annals of Internal Medicine, 138 (3), 215. doi: 10.7326/0003-4819-138-3-200302040-00015
  13. Way2Drug. Available at: http://www.pharmaexpert.ru/PASSOnline/index.php
  14. Bessarabov, V. I., Zderko, N. P. (2013). Possible influenza efficacy of certain active pharmaceutical ingredients. Gerontologija, 1, 51–59.
  15. Bessarabov, V. I., Pal'chevskaja, T. A., Kuryshko, G. G., Kuz'mina, G. I., Tarasenko, A. V. (2014). Pharmaceutical analysis of complex geriatric drugs. Gerontologija, 2 (3), 338–344.
  16. Poroikov, V. V., Filimonov, D. A., Ihlenfeldt, W.-D., Gloriozova, T. A., Lagunin, A. A., Borodina, Y. V. (2003). PASS Biological Activity Spectrum Predictions in the Enhanced Open NCI Database Browser. Journal of Chemical Information and Computer Sciences, 43 (1), 228–236. doi: 10.1021/ci020048r
  17. Bessarabov, V. I., Palchevska, T. A., Kuzmina, G. І. (2015). Study in silico endo- and exo toxicity some biologically active substances from the extract of melissa officinalis l. Gerontologija, 3 (1), 96–107.
  18. Lagunin, A., Zakharov, A., Filimonov, D., Poroikov, V. (2011). QSAR Modelling of Rat Acute Toxicity on the Basis of PASS Prediction. Molecular Informatics, 30 (2-3), 241–250. doi: 10.1002/minf.201000151

Downloads

Published

2016-10-30

How to Cite

Данилко, Д. І., Бессарабов, В. І., & Пальчевська, Т. А. (2016). Design of geriatric drug potentially increasing adiponectin expression. ScienceRise: Pharmaceutical Science, (3 (3), 55–59. https://doi.org/10.15587/2519-4852.2016.81471

Issue

No. 3 (3) (2016)

Section

Pharmaceutical Science

License

Copyright (c) 2016 Діана Іванівна Данилко, Володимир Іванович Бессарабов, Тетяна Андріївна Пальчевська

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons Attribution 4.0 International License copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.

3. Authors have the right to store the final accepted version of the article in an institutional, thematic, or any other repository to ensure visibility and accessibility.